Study of ontunisertib for fibrostenosing Crohn's disease
Part of Digestive system, Immune system & allergy clinical trials.
This trial tests an investigational drug called ontunisertib versus a placebo in people with Crohn's disease that has caused narrowing (strictures) in the small intestine. It aims to see if the drug can help without needing surgery or other procedures.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have Crohn's disease in the ileum (last part of the small intestine) or ileum and colon for at least 12 weeks
- You must have at least one narrowed area in the ileum that a scope cannot pass through
- You must have symptoms like partial blockages or need to limit what you eat because of the narrowing
- You must be on a stable treatment for Crohn's and agree not to change it during the study
- Your body mass index (BMI) must be between 18 and 34.9
- You cannot have certain heart valve problems or a weak heart pump
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how a new drug, ontunisertib, is processed by the body and eliminated. Healthy men will take a single dose with a tiny radioactive tracer so researchers can track the drug.
This study tests a medicine called tirzepatide to see if it can help people with active Crohn’s disease who have not responded to multiple prior treatments. It focuses on how the drug might work beyond just reducing inflammation.
This trial tests new therapies for people with moderate to severe Crohn's disease or ulcerative colitis. It may help if your standard treatments aren't working well enough.
This trial tests an oral medicine called RXC008 to see if it can help people with Crohn's disease who have narrowed areas in their small intestine (strictures). It aims to reduce symptoms and improve quality of life without needing surgery or dilation.
This trial tests new targeted therapies for adults with moderate to severe Crohn's disease that hasn't improved with standard treatments. The goal is to see if these drugs can reduce inflammation and improve symptoms.
This trial tests whether risankizumab can help people with a type of Crohn's disease where the intestine becomes narrowed (fibrostenotic) and causes symptoms like cramping or vomiting. The goal is to see if the drug can reduce inflammation and improve these blockages.
Hear when a new Fibrostenotic Crohn's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.